After Guggenheim and Leerink Partners gave Blueprint Medicines (NASDAQ: BPMC) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Marc Frahm maintained a Buy rating on Blueprint Medicines yesterday. The company’s shares closed on Friday at $69.54.
According to TipRanks.com, Frahm is a 2-star analyst with an average return of 0.5% and a 41.7% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Loxo Oncology, and Incyte Corp.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Blueprint Medicines with a $104 average price target, a 49.6% upside from current levels. In a report issued on September 24, Leerink Partners also initiated coverage with a Buy rating on the stock with a $105 price target.
The company has a one-year high of $109 and a one-year low of $57.44. Currently, Blueprint Medicines has an average volume of 326.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.